Aldeyra Therapeutics
ALDX
72 hedge funds and large institutions have $88.9M invested in Aldeyra Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 10 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 19
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.28% less ownership
Funds ownership: 61.44% → 61.15% (-0.28%)
5% less funds holding
Funds holding: 76 → 72 (-4)
12% less capital invested
Capital invested by funds: $101M → $88.9M (-$12.4M)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
63% less call options, than puts
Call options by funds: $76K | Put options by funds: $207K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.58M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.35M |
| 3 |
6CM
683 Capital Management
New York
|
+$1.21M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$498K |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$497K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.95M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.35M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$1.31M |
| 4 |
Renaissance Technologies
New York
|
-$541K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$383K |
ALDX Hedge Fund Activity: Q3 2019 in Review
72 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2019, worth a combined $88.9M — down 12% from $101M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ALDX and 6 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 30 added.
The largest buyer was Millennium Management, adding an estimated $1.58M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.95M sold.
- 72 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2019, down from 76 in Q2 2019.
- Funds reported $88.9M of Aldeyra Therapeutics stock for Q3 2019, down 12% quarter-over-quarter.
- 6 funds opened new Aldeyra Therapeutics positions in Q3 2019 and 10 closed out, a net change of -4 holders.
- The largest Aldeyra Therapeutics buyer in Q3 2019 was Millennium Management, an estimated $1.58M added.
- The largest Aldeyra Therapeutics seller in Q3 2019 was Point72 Asset Management, an estimated $1.95M sold.
Based on aggregated 13F filings for Q3 2019.